PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
SLDB vs. RXRX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SLDB and RXRX is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

SLDB vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Solid Biosciences Inc. (SLDB) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

-60.00%-40.00%-20.00%0.00%20.00%40.00%60.00%SeptemberOctoberNovemberDecember2025February
-54.56%
56.25%
SLDB
RXRX

Key characteristics

Sharpe Ratio

SLDB:

-0.57

RXRX:

0.09

Sortino Ratio

SLDB:

-0.55

RXRX:

0.80

Omega Ratio

SLDB:

0.94

RXRX:

1.09

Calmar Ratio

SLDB:

-0.49

RXRX:

0.09

Martin Ratio

SLDB:

-0.94

RXRX:

0.15

Ulcer Index

SLDB:

51.60%

RXRX:

49.42%

Daily Std Dev

SLDB:

83.38%

RXRX:

87.62%

Max Drawdown

SLDB:

-99.76%

RXRX:

-88.97%

Current Drawdown

SLDB:

-99.48%

RXRX:

-74.52%

Fundamentals

Market Cap

SLDB:

$161.02M

RXRX:

$4.04B

EPS

SLDB:

-$3.11

RXRX:

-$1.91

Total Revenue (TTM)

SLDB:

$0.00

RXRX:

$54.29M

Gross Profit (TTM)

SLDB:

-$1.56M

RXRX:

$14.55M

EBITDA (TTM)

SLDB:

-$82.81M

RXRX:

-$262.33M

Returns By Period

In the year-to-date period, SLDB achieves a 0.75% return, which is significantly lower than RXRX's 55.77% return.


SLDB

YTD

0.75%

1M

28.34%

6M

-54.57%

1Y

-59.00%

5Y*

-39.03%

10Y*

N/A

RXRX

YTD

55.77%

1M

64.02%

6M

56.23%

1Y

-15.29%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

SLDB vs. RXRX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SLDB
The Risk-Adjusted Performance Rank of SLDB is 1919
Overall Rank
The Sharpe Ratio Rank of SLDB is 1616
Sharpe Ratio Rank
The Sortino Ratio Rank of SLDB is 1818
Sortino Ratio Rank
The Omega Ratio Rank of SLDB is 2121
Omega Ratio Rank
The Calmar Ratio Rank of SLDB is 1717
Calmar Ratio Rank
The Martin Ratio Rank of SLDB is 2424
Martin Ratio Rank

RXRX
The Risk-Adjusted Performance Rank of RXRX is 4949
Overall Rank
The Sharpe Ratio Rank of RXRX is 4848
Sharpe Ratio Rank
The Sortino Ratio Rank of RXRX is 5353
Sortino Ratio Rank
The Omega Ratio Rank of RXRX is 4949
Omega Ratio Rank
The Calmar Ratio Rank of RXRX is 4949
Calmar Ratio Rank
The Martin Ratio Rank of RXRX is 4646
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SLDB vs. RXRX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Solid Biosciences Inc. (SLDB) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for SLDB, currently valued at -0.57, compared to the broader market-2.000.002.004.00-0.570.09
The chart of Sortino ratio for SLDB, currently valued at -0.55, compared to the broader market-6.00-4.00-2.000.002.004.006.00-0.550.80
The chart of Omega ratio for SLDB, currently valued at 0.94, compared to the broader market0.501.001.502.000.941.09
The chart of Calmar ratio for SLDB, currently valued at -0.51, compared to the broader market0.002.004.006.00-0.510.09
The chart of Martin ratio for SLDB, currently valued at -0.94, compared to the broader market-10.000.0010.0020.0030.00-0.940.15
SLDB
RXRX

The current SLDB Sharpe Ratio is -0.57, which is lower than the RXRX Sharpe Ratio of 0.09. The chart below compares the historical Sharpe Ratios of SLDB and RXRX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.00SeptemberOctoberNovemberDecember2025February
-0.57
0.09
SLDB
RXRX

Dividends

SLDB vs. RXRX - Dividend Comparison

Neither SLDB nor RXRX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SLDB vs. RXRX - Drawdown Comparison

The maximum SLDB drawdown since its inception was -99.76%, which is greater than RXRX's maximum drawdown of -88.97%. Use the drawdown chart below to compare losses from any high point for SLDB and RXRX. For additional features, visit the drawdowns tool.


-95.00%-90.00%-85.00%-80.00%-75.00%SeptemberOctoberNovemberDecember2025February
-94.86%
-74.52%
SLDB
RXRX

Volatility

SLDB vs. RXRX - Volatility Comparison

The current volatility for Solid Biosciences Inc. (SLDB) is 27.18%, while Recursion Pharmaceuticals, Inc. (RXRX) has a volatility of 29.24%. This indicates that SLDB experiences smaller price fluctuations and is considered to be less risky than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


15.00%20.00%25.00%30.00%35.00%40.00%SeptemberOctoberNovemberDecember2025February
27.18%
29.24%
SLDB
RXRX

Financials

SLDB vs. RXRX - Financials Comparison

This section allows you to compare key financial metrics between Solid Biosciences Inc. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab